



# Biotech Daily

Monday July 18, 2022

*Daily news on ASX-listed biotechnology companies*

- \* **ASX UP, BIOTECH EVEN: DIMERIX UP 11%; NOVA EYE DOWN 9.5%**
- \* **RHINOMED, SURESCREEN 10m RHINOSWAB SUPPLY DEAL**
- \* **HERAMED, PROJECT ROZANA REMOTE FOETAL TEST FOR PALESTINE**
- \* **RESAPP VOTES ON \$127m PFIZER ACQUISITION**
- \* **SILES HEALTH TO USE GENETIC TECHNOLOGIES GENETYPE TESTS**
- \* **CRESO EXPANDS PSILOCYBIN PTSD TRIAL; SSRIs INCLUDED**
- \* **EMYRIA, UWA INCREASE MDMA ANALOGUES**
- \* **4D TO RELEASE 86m ASX ESCROW SHARES, 13m OPTIONS**
- \* **IMUGENE APPOINTS MIKE TONROE CFO**

## MARKET REPORT

The Australian stock market was up 1.23 percent on Monday July 18, 2022, with the ASX200 up 81.5 points to 6,687.1 points. Sixteen of the Biotech Daily Top 40 stocks were up, 15 fell, eight traded unchanged and one was untraded.

Dimerix was the best, up 1.5 cents or 10.7 percent to 15.5 cents, with 128,999 shares traded.

Emvision climbed 9.4 percent; Imugene improved six percent; Polynovo and Volpara were up more than five percent; Alcidion, Mesoblast and Starpharma were up more than three percent; Nanosonics and Next Science rose two percent or more; Atomo, Paradigm, Pro Medicus and Proteomics were up more than one percent; with Cyclopharm, Medical Developments and Resmed up by less than one percent.

Nova Eye led the falls, down two cents or 9.5 percent to 19 cents, with 100,000 shares traded. Prescient lost 8.1 percent; Uscom was down 7.1 percent; Pharmaxis and Universal Biosensors fell more than four percent; Kazia was down 3.6 percent; Compumedics and Genetic Signatures shed two percent or more; Avita, Cochlear, Impedimed and Oncosil were down more than one percent; with Clinuvel, CSL, Neuren, Opthea and Telix down by less than one percent.

## RHINOMED

Rhinomed says it will supply more than 10 million Rhinoswabs to Surescreen Australia for its respiratory tests in Australia, New Zealand, Singapore and the South Pacific.

Rhinomed said its Rhinoswab and Rhinoswab Junior would be used for the Surescreen tests for upper respiratory diseases, including severe-acute-respiratory-syndrome coronavirus-2 (Sars-Cov-2) and had the potential to earn more than 160 percent of its \$3.75 million revenue for the six months to December 31, 2021, which Biotech Daily calculates to be more than \$6.0 million.

The company said it would supply at least 10 million swabs to Surescreen over two years, but the pricing was “commercial in confidence” with first orders expected this month.

Rhinomed said that the Sydney-based Surescreen Australia was an affiliate of the Derby, England-based Surescreen Diagnostics.

The company said the first product available was the Australian approved Surescreen rapid antigen test for Sars-Cov-2, which used its Rhinoswab Junior nasal swab and was designed specifically for children aged four to 12 years.

Rhinomed said its nasal swab products were “significantly easier, standardized and more comfortable” than traditional nasal swabbing products, which might increase testing levels and reliability, especially in children.

Rhinomed chief executive officer Michael Johnson said “the opportunity to include the Rhinoswab and Rhinoswab Junior in their extensive range of upper respiratory diseases tests is a major milestone for the company”.

“We know that testing children can be traumatic and difficult ... this new test kit changes the paradigm and getting it into every Australian home is our priority,” Mr Johnson said.

Rhinomed was up two cents or 14.3 percent to 16 cents.

## HERAMED

Heramed says it will provide remote foetal cardiac monitoring to Palestinian mothers in a collaboration with Tel Aviv’s Sheba Medical Centre through Australia’s Project Rozana.

Heramed said Project Rozana was a program which delivered improved healthcare access to Palestinians, engaged in professional development and capacity building to contribute to an independent healthcare system, and attempted to reduce the mortality rate of babies born in Gaza and the West Bank.

The company said that with Sheba’s virtual obstetrics and gynaecology department it would establish a remote obstetrics and gynaecology unit in the rural Hebron area, using its remote foetal assessment technology, and operated by Palestinian healthcare teams.

Heramed said the initial launch would include 30 pregnant mothers, with virtual clinics providing services to women in three target communities, screening for health issues and referring for medical treatment if necessary, and it expected revenue of \$US15,000 (\$A22,055) through its software as a service model.

Heramed chief financial officer Sivan Sadan said “by leveraging our technology, the Rozana Project will significantly improve the care of Palestinian expectant mothers and hopefully, save many lives”.

Project Rozana executive director Ronit Zimmer said that “enabling Palestinians to provide healthcare in their remote communities lays the groundwork for an empowered people”.

“The training at Sheba will enable local healthcare workers to operate virtual clinics in remote areas, eliminating many logistical, bureaucratic and security obstacles for rural residents seeking quality healthcare,” Ms Zimmer said.

Heramed was unchanged at 12 cents.

## RESAPP HEALTH

Resapp says it will hold a shareholder meeting to vote on the proposed acquisition by Pfizer Australia Holdings Pty on August 19, 2022.

Last month, Resapp said Pfizer would pay about \$127 million, or 14.6 cents a share, for 100 percent of the company after it failed a confirmatory data readout condition for its cough diagnostic screening test (BD: Jun 21, 2022).

In a separate announcement, the company said that the Supreme Court of New South Wales ordered it to convene a meeting of shareholders and vote on the acquisition scheme, as well as release an explanatory statement providing information on the scheme.

Separately, Resapp said the Australian Competition and Consumer Commission did not find it necessary to conduct a public review of the acquisition after it considered the information provided by Resapp and Pfizer.

Resapp said the meeting would be held virtually and at the Four Seasons Hotel, 199 George Street, Sydney, on August 19, 2022, at 2pm (AEST).

Resapp was unchanged at 13.5 cents with 16.75 million shares traded.

## GENETIC TECHNOLOGIES

Genetic Technologies says it has partnered with the Melbourne-based Siles Health to use its Genotype Multi-Risk test in nine Siles obstetrics and gynaecology clinics.

Genetic Technologies said Siles Health was a franchise which operated nine clinics in Victoria and treated more than 15,000 patients each year.

The company did not disclose the commercial terms for the agreement, but said that it did not stipulate minimum numbers of tests to be purchased, had no fixed term and no material termination conditions.

Genetic Technologies fell 0.05 cents or 12.5 percent to 0.35 cents with 6.8 million shares traded.

## CRESO PHARMA

Creso says subsidiary Halucenex Life Sciences has expanded its up-to 20 patients, phase II trial of psilocybin for treatment-resistant post-traumatic stress disorder.

In February, Creso said Health Canada had approved its planned trial of psilocybin for post-traumatic stress disorder (BD: Feb 28, 2022).

Today, the company said it would apply for amendments to its approved clinical trial authorisation to include cohorts currently using selective serotonin reuptake inhibitors (SSRIs or antidepressants), and not require patients to stop using prescribed medications for a week prior to the potential trials' commencement.

Creso said the decision to expand the trial came after engagement with veterans affairs groups and others, and would provide it with additional data on how psilocybin interacts with commonly-used medication for post-traumatic stress disorder.

Creso said it expected a receipt of an amended clinical trial authorization "shortly" and that subject to ethics approval, it would begin patient recruitment and administer first doses.

The company said it had appointed the London, Ontario-based KGK Science Inc as its contract research organization.

Halucenex chief executive officer Bill Fleming said the company had been "completely inundated from several groups regarding potential participation in the study, highlighting the demand for an alternative treatment solution to pharmacological interventions".

Creso was up 0.3 cents or 6.8 percent to 4.7 cents with 4.6 million shares traded.

### EMYRIA

Emyria with the University of Western Australia says it has developed 19 new 3,4 methylene-dioxy-meth-amphetamine (MDMA) analogues and sent them for screening. Emyria said the new compounds brought its MDMA-like analogue library to more than 125 compounds and it had developed 45 analogues under its partnership with Perth's University of Western Australia.

The company said it would prioritize drug-assisted psychotherapy for major mental health disorders, small molecule treatments for neurological disorders, and treatments for non-neurological disorders, in its synthesis program.

Emyria fell one cent or 4.55 percent to 21 cents.

### 4D MEDICAL

4D Medical says it will release 85,536,074 shares and 12,770,998 options from ASX escrow on August 8, 2022.

According to its most recent filing, 4D said following the release of shares, it would have a total of 294,491,837 shares available for trading, with no further shares held in ASX escrow.

4D Medical fell half a cent or one percent to 48.5 cents.

### IMUGENE

Imugene says it has appointed Mike Tonroe as its chief financial officer, expected to begin in "early September 2022".

Imugene said Mr Tonroe was previously the chief financial officer and company secretary at Genetic Technologies and Opthea, as well as the Australian Synchrotron.

The company said Mr Tonroe held a Bachelor of Business Studies from England's Buckingham University.

Imugene was up 1.5 cents or six percent to 26.5 cents with 33.5 million shares traded.